Free Trial

TransMedics Group (TMDX) Earnings Date, Estimates & Call Transcripts

TransMedics Group logo
$87.18 +0.34 (+0.39%)
Closing price 04:00 PM Eastern
Extended Trading
$85.65 -1.53 (-1.75%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group Earnings Summary

Upcoming Q4
Earnings Date
Apr. 29After Market ClosesEstimated
Consensus EPS
(Oct. 28)
$0.29
Actual EPS
(Oct. 28)
$0.12 Missed By -$0.17
Actual Revenue
(Oct. 28)
$108.76M

TransMedics Group announced Q3 2024 earnings on October 28, 2024, reporting an EPS of $0.12, which missed the consensus estimate of $0.29 by $0.17. Quarterly revenue rose 63.7% year-over-year to $108.76 million, below analysts' expectations of $115 million. With a trailing EPS of $1.01 and a P/E Ratio of 92.75, TransMedics Group's earnings are expected to grow 43.00% next year, from $1.00 to $1.43 per share.

Q3 2024 Earnings Resources

TMDX Upcoming Earnings

TransMedics Group's Q1 2025 earnings is scheduled for Tuesday, April 29, 2025, with a conference call scheduled on Friday, May 2, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get TransMedics Group Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransMedics Group and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

TMDX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TMDX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.
Remove Ads

TransMedics Group Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251$0.30$0.30$0.30
Q2 20251$0.36$0.36$0.36
Q3 20251$0.45$0.45$0.45
Q4 20251$0.61$0.61$0.61
FY 20254$1.72$1.72$1.72
Q1 20261$0.50$0.50$0.50
Q2 20261$0.60$0.60$0.60
Q3 20261$0.59$0.59$0.59
Q4 20261$0.84$0.84$0.84
FY 20264$2.53$2.53$2.53
Remove Ads

TransMedics Group Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
4/29/2025
(Estimated)
--------
10/28/2024Q3 2024$0.29$0.12 -$0.17$0.12$115.00M$108.76M
7/31/2024Q2 2024$0.21$0.35+$0.14$0.35$98.84M$114.30M
4/30/2024Q1 2024-$0.05$0.35+$0.40$0.35$83.78M$96.90M
2/26/2024Q4 2023-$0.10$0.12+$0.22$0.12$68.49M$81.20M
11/6/2023Q3 2023-$0.18-$0.12+$0.06$0.54$48.05M$66.43M
8/3/2023Q2 2023-$0.15-$0.03+$0.12-$0.03$42.42M$42.46M
5/1/2023Q1 2023-$0.25-$0.08+$0.17-$0.08$36.05M$41.60M

TransMedics Group Earnings - Frequently Asked Questions

TransMedics Group has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, April 29th, 2025 based off last year's report dates. Learn more on TMDX's earnings history.

TransMedics Group updated its FY 2025 earnings guidance on Thursday, February, 27th. The company issued revenue guidance of $530.0 million-$552.0 million, compared to the consensus revenue estimate of $521.6 million.

In the previous quarter, TransMedics Group (NASDAQ:TMDX) missed the analysts' consensus estimate of $0.29 by $0.17 with a reported earnings per share (EPS) of $0.12. Learn more on analysts' earnings estimate vs. TMDX's actual earnings.

The conference call for TransMedics Group's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for TransMedics Group's latest earnings report can be read online.
Read Transcript

TransMedics Group (NASDAQ:TMDX) has a recorded annual revenue of $441.54 million.

TransMedics Group (NASDAQ:TMDX) has a recorded net income of -$25.03 million. TMDX has generated $1.01 earnings per share over the last four quarters.

TransMedics Group (NASDAQ:TMDX) has a trailing price-to-earnings ratio of 92.75 and a forward price-to-earnings ratio of 87.18.

TransMedics Group's earnings are expected to grow from $1.00 per share to $1.43 per share in the next year, which is a 43.00% increase.

More Earnings Resources from MarketBeat

Remove Ads


This page (NASDAQ:TMDX) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners